The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
CDDO-Me Protects Normal Lung and Breast Epithelial Cells but Not Cancer Cells from Radiation
Open accessAbstract
Although radiation therapy is commonly used for treatment for many human diseases including cancer, ionizing radiation produces reactive oxygen species that can damage both cancer and healthy cells. Synthetic triterpenoids, including CDDO-Me, act as anti-inflammatory and antioxidant modulators primarily by inducing the transcription factor Nrf2 to activate downstream genes containing antioxidant response elements (AREs). In the present series of experiments, we determined if CDDO-Me can be used as a radioprotector in normal non-cancerous human lung and breast epithelial cells, in comparison to lung and breast cancer cell lines. A panel of normal non-cancerous, partially cancer progressed, and cancer cell lines from both lung and breast tissue was exposed to gamma radiation with and without pre-treatment with CDDO-Me. CDDO-Me was an effective radioprotector when given ∼18 hours before radiation in epithelial cells (average dose modifying factor (DMF) = 1.3), and Nrf2 function was necessary for CDDO-Me to exert these radioprotective effects. CDDO-Me did not protect cancer lines tested from radiation-induced cytotoxicity, nor did it protect experimentally transformed human bronchial epithelial cells (HBECs) with progressive oncogenic manipulations. CDDO-Me also protected human lymphocytes against radiation-induced DNA damage. A therapeutic window exists in which CDDO-Me protects normal cells from radiation by activating the Nrf2 pathway, but does not protect experimentally transformed or cancer cell lines. This suggests that use of this oral available, non-toxic class of drug can protect non-cancerous healthy cells during radiotherapy, resulting in better outcomes and less toxicity for patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Figure 2 Pre-treatment with CDDO-Me decreases IR-induced DNA damage in a variety of non-cancerous cells. CDDO-Me decreases radiation-induced DNA damage in the alkaline comet assay in bronchial and mammary epithelial cells as well as human lymphocytes. (A) HBEC 3KT, (B) HME1, and (C) PBMCs were treated with CDDO-Me 18 hours prior to IR, then mounted on slides 30 min post-IR. Data analyzed and calculated using Open Comet software [tail moment = tail length x tail DNA percentage]. Mean ± SEM of >50 cells per condition, *p<0.05 using t-test (compared to 3 Gy DMSO). **p<0.01, using T-test (compared to 0 Gy DMSO).](https://figures.cochat.ai/paper-figures/11c008f0f367482583ad869dab9f0ab1/cddo-me-protects-normal-lung-and-breast-epithelial-cells-but-not-cancer-cells-figure-2.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling
Ray, P. D., Huang, B.-W., & Tsuji, Y. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.01.008 · Cited by 4,373 · cited 1×
“1A) [6].”
Pearce, M. S., Salotti, J. A., Little, M. P., McHugh, K., Lee, C., Kim, K. P., Howe, N. L., Ronckers, C. M., Rajaraman, P., Craft, A. W., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60815-0 · Cited by 3,735
Ward, J. F. (1988) · Progress in Nucleic Acid Research and Molecular Biology · doi:10.1016/s0079-6603(08)60611-x · Cited by 1,492 · cited 1×
“Although radiation therapy is a common treatment for cancer patients, ionizing radiation (IR) produces reactive oxygen species (ROS) and is known to damage cellular components in healthy cells, leading to damaged bases and DNA breaks, resulting in chromosomal aberrations, mutagenesis, carcinogenesis, and cell death [1…”
Ramos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102 · cited 3×
“Mouse embryonic fibroblast (MEF) cells Nrf2-heterozygous (+/2) and nrf2-deficient (2/2) cells were the generous gift of Ralph DeBerardinis (Children’s Medical Center Research Institute, UT Southwestern Medical Center, Dallas, TX) [26].”
InfluentialDysfunctional KEAP1–NRF2 Interaction in Non-Small-Cell Lung Cancer
Singh, A., Misra, V., Thimmulappa, R. K., Lee, H., Ames, S., Hoque, M. O., Herman, J. G., Baylin, S. B., Sidransky, D., Gabrielson, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030420 · Cited by 1,060 · cited 1×
“Interestingly, the Nrf2 pathway is commonly dysregulated in cancers, providing tumors added detoxifying potential against cellular insults [7–9].”
Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes
Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105351 · Cited by 890
OpenComet: An automated tool for comet assay image analysis
Gyori, B. M., Venkatachalam, G., Thiagarajan, P. S., Hsu, D., & Clement, M.-V. (2014) · Redox Biology · doi:10.1016/j.redox.2013.12.020 · Cited by 717 · cited 1×
“Approximately 50 cells per condition were analyzed using OpenComet software [28].”
MethodRadiation oncology: a century of achievements
Bernier, J., Hall, E. J., & Giaccia, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1451 · Cited by 628 · cited 1×
“Although radiation therapy is a common treatment for cancer patients, ionizing radiation (IR) produces reactive oxygen species (ROS) and is known to damage cellular components in healthy cells, leading to damaged bases and DNA breaks, resulting in chromosomal aberrations, mutagenesis, carcinogenesis, and cell death [1…”
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins
Ramirez, R. D., Sheridan, S., Girard, L., Sato, M., Kim, Y., Pollack, J., Peyton, M., Zou, Y., Kurie, J. M., DiMaio, J. M., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-3703 · Cited by 607 · cited 1×
“Human bronchial epithelial cells (HBECs) were obtained from central lung bronchi and immortalized using ectopic expression of human telomerase reverse transcriptase (hTERT; T) and cyclin-dependent kinase 4 (CDK4; K) as described previously [22].”
MethodSelf-citationSolis, L. M., Behrens, C., Dong, W., Suraokar, M., Ozburn, N. C., Moran, C. A., Corvalan, A. H., Biswal, S., Swisher, S. G., Bekele, B. N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3352 · Cited by 428 · cited 1×
“Interestingly, the Nrf2 pathway is commonly dysregulated in cancers, providing tumors added detoxifying potential against cellular insults [7–9].”
Liby, K. T., & Sporn, M. B. (2012) · Pharmacological Reviews · doi:10.1124/pr.111.004846 · Cited by 405 · cited 1×
“As the concentration of CDDO-Me increases into the micromolar range, it can induce differentiation and inhibit cell proliferation, eventually leading to cell death via apoptosis through IKK and NF-kB pathways [12].”
The Keap1–Nrf2 system in cancers: stress response and anabolic metabolism
Mitsuishi, Y., Motohashi, H., & Yamamoto, M. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00200 · Cited by 392 · cited 1×
“Interestingly, the Nrf2 pathway is commonly dysregulated in cancers, providing tumors added detoxifying potential against cellular insults [7–9].”
Assessing the risk of second malignancies after modern radiotherapy
Newhauser, W. D., & Durante, M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3069 · Cited by 380 · cited 1×
“Radiation exposure has been specifically linked to secondary cancers later in life [3–5].”
Liby, K., Hock, T., Yore, M. M., Suh, N., Place, A. E., Risingsong, R., Williams, C. R., Royce, D. B., Honda, T., Honda, Y., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4539 · Cited by 283 · cited 1×
“Additional work by the Liby and Sporn group show that CDDO compounds activate Nrf2 downstream effectors, such as heme oxygenase-1 (HO1), as well as other pathways in both transgenic and wildtype mouse models [14, 17, 18].”
Shanmugam, M. K., Dai, X., Kumar, A. P., Tan, B. K. H., Sethi, G., & Bishayee, A. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.01.016 · Cited by 271 · cited 1×
“There are published reports showing that higher doses of CDDO-Me and other triterpenoids (above 1 mM) can inhibit cancer cell growth and induce cancer cell death in a multitude of cancer types [16, 37].”
Sato, M., Vaughan, M. B., Girard, L., Peyton, M., Lee, W., Shames, D. S., Ramirez, R. D., Sunaga, N., Gazdar, A. F., Shay, J. W., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2521 · Cited by 263
Self-citationHong, D. S., Kurzrock, R., Supko, J. G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J. P., Meyer, C. J., Ferguson, D. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2703 · Cited by 236 · cited 1×
“CDDO-Me has shown antitumor activity in lymphoma patients in a phase I human trial and prevents formation of estrogen receptor-negative mammary tumors in mouse models of breast cancer [13, 14].”
Chemical radioprotection: A critical review of amifostine as a cytoprotector in radiotherapy
Andreassen, C. N., Grau, C., & Lindegaard, J. C. (2003) · Seminars in Radiation Oncology · doi:10.1053/srao.2003.50006 · Cited by 200 · cited 3×
“In addition, amifostine has high cytotoxic activity against normal cells and has serious side effects such as hypotension and neuropathies [30].”
Shay, J. W., van der Haegen, B. A., Ying, Y., & Wright, W. E. (1993) · Experimental Cell Research · doi:10.1006/excr.1993.1283 · Cited by 164 · cited 1×
“All HMECs were cultured in serum-free conditions as previously described and were mycoplasma free and DNA fingerprinted [25].”
Self-citationKim, S. B., Pandita, R. K., Eskiocak, U., Ly, P., Kaisani, A., Kumar, R., Cornelius, C., Wright, W. E., Pandita, T. K., & Shay, J. W. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1207718109 · Cited by 159 · cited 3×
“Similar effects have been observed in other studies [20], but since there is never a 100% decrease of Nrf2 with shRNA knockdowns, there may be residual Nrf2 even in the sh-Nrf2 cells.”
Self-citationLiby, K. T., Royce, D. B., Williams, C. R., Risingsong, R., Yore, M. M., Honda, T., Gribble, G. W., Dmitrovsky, E., Sporn, T. A., & Sporn, M. B. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4534 · Cited by 146 · cited 1×
“) [10, 11].”
Shay, J. W., Tomlinson, G. E., Piatyszek, M. A., & Gollahon, L. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.1.425 · Cited by 145 · cited 1×
“HMEC50 cells were originally derived from the noncancerous breast tissue of a female diagnosed with Li-Fraumeni syndrome (TP53 heterozygous) as previously described [24].”
MethodSelf-citationLevy, S., & Forman, H. J. (2010) · IUBMB Life · doi:10.1002/iub.314 · Cited by 142 · cited 1×
“Interestingly, c-myc has been identified as an Nrf2-interacting protein [36], but a single mutation is unlikely responsible for loss of CDDO-Me effects.”
Synthetic Triterpenoids Prolong Survival in a Transgenic Mouse Model of Pancreatic Cancer
Liby, K. T., Royce, D. B., Risingsong, R., Williams, C. R., Maitra, A., Hruban, R. H., & Sporn, M. B. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-10-0197 · Cited by 91
A Method for Determining Dose-modification Factors
Pike, M. C., & Alper, T. (1964) · British Journal of Radiology · doi:10.1259/0007-1285-37-438-458 · Cited by 90 · cited 1×
“Cell survival measurements were fitted using a linear quadratic equation [SF5exp (2aD 2 bD(2))] (SF: surviving fraction; D: radiation dose in Gy) using GraphPad Prism, and dose-modifying factors (DMF) calculated for each as a measure of radioprotection as described [27].”
MethodWang, Y., Zhe, H., & Zhao, R. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-30 · Cited by 84 · cited 2×
“Additionally, the ethylamide analogue of CDDO (CDDOEa) can prevent cancer progression in mouse models of lung and prostate cancer [15, 16].”
Liby, K. T., Risingsong, R., Royce, D. B., Williams, C. R., Yore, M. M., Honda, T., Gribble, G. W., Lamph, W. W., Vannini, N., Sogno, I., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0040 · Cited by 77
Honda, T., Yoshizawa, H., Sundararajan, C., David, E., Lajoie, M. J., Favaloro, F. G., Janosik, T., Su, X., Honda, Y., Roebuck, B. D., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101445p · Cited by 72 · cited 1×
“) [10, 11].”
Radiation promotes malignant progression of glioma cells through HIF-1alpha stabilization
Kim, Y.-H., Yoo, K.-C., Cui, Y., Uddin, N., Lim, E.-J., Kim, M., Nam, S.-Y., Kim, I., Suh, Y., & Lee, S. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.07.048 · Cited by 64 · cited 1×
“Radiation has been shown to stabilize hypoxia inducible factor (HIF-1a) by activating p38 MAPK and resulting in the decreased half-life of its E3 specific ligase, protein von Hippel-Lindau [34].”
Liby, K. T., Risingsong, R., Royce, D. B., Williams, C. R., Ma, T., Yore, M. M., & Sporn, M. B. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0085 · Cited by 57 · cited 1×
“Additionally, the ethylamide analogue of CDDO (CDDOEa) can prevent cancer progression in mouse models of lung and prostate cancer [15, 16].”
The role of amifostine as a radioprotector.
Wasserman, T. H., & Brizel, D. M. (2001) · PubMed · Cited by 52
CDDO-Me protects against space radiation-induced transformation of human colon epithelial cells
Eskiocak, U., Kim, S. B., Roig, A. I., Kitten, E., Batten, K., Cornelius, C., Zou, Y. S., Wright, W. E., & Shay, J. W. (2010) · Radiation Research · doi:10.1667/rr2155.1 · Cited by 36 · cited 1×
“Furthermore, CDDO-Me has been shown to be an effective radioprotector in human colonic epithelial cells [20, 21].”
Self-citationLate effects of early childhood cancer therapy.
Meadows, A. T., Gallagher, J. A., & Bunin, G. R. (1992) · PubMed · Cited by 32
Daróczi, B., Kari, G., Ren, Q., Dicker, A. P., & Rodeck, U. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0198 · Cited by 32 · cited 1×
“At doses that inhibit NF-kB, a CDDO analog significantly increases survival and decreases apoptosis in different tissues of lethally irradiated zebrafish embryos [19].”
Amifostine induces anaerobic metabolism and hypoxia-inducible factor 1α
Koukourakis, M. I., Giatromanolaki, A. N., Chong, W., Simopoulos, C., Polychronidis, A., Sivridis, E., & Harris, A. L. (2003) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0691-z · Cited by 28 · cited 1×
“There have been reports that amifostine induces HIF-1a in both cell culture and mouse tissues [35].”
Human Health Effects of Low Doses of Ionizing Radiation: The BEIR III Controversy
Radford, E. P. (1980) · Radiation Research · doi:10.2307/3575478 · Cited by 27 · cited 1×
“Unfortunately, normal tissue damage follows an even steeper increase with increasing radiation dose [32].”
Radiation Carcinogenesis Risk Assessments for Never-smokers
Cucinotta, F. A., Chappell, L. J., Kim, M. Y., & Wang, M. (2012) · Health Physics · doi:10.1097/hp.0b013e318267b3ad · Cited by 25 · cited 1×
“Radiation exposure has been specifically linked to secondary cancers later in life [3–5].”
Liby, K. T. (2013) · Dose-Response · doi:10.2203/dose-response.13-018.liby · Cited by 10 · cited 1×
“CDDO-Me, and other compounds in the same triterpenoid family, have been shown to have chemoprotective properties in addition to radioprotective properties [39].”
Toxicity of small cell lung cancer treatment
Casas, F., & Viñolas, N. (2004) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2003.12.007 · Cited by 3 · cited 2×
“The partial protection of human lymphocytes with CDDO-Me is particularly important since significant hematological toxicities are associated with radiation therapy for lung and breast cancers [29].”
Cited by
Nrf2 promotes survival following exposure to ionizing radiation
Sekhar, K. R., & Freeman, M. L. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.04.035 · Cited by 109
Marampon, F., Gravina, G. L., Festuccia, C., Popov, V. M., Colapietro, E. A., Sanità, P., Musio, D., Felice, F. D., Lenzi, A., Jannini, E. A., et al. (2015) · Journal of Endocrinological Investigation · doi:10.1007/s40618-015-0381-9 · Cited by 69
“Furthermore, recent findings suggesting that antioxidants may induce apoptosis in cancer cells may further render these compounds an useful adjunctive treatment together with antitumor agents [16].”
BackgroundPredicting Radiation-Induced Lung Injury in Patients With Lung Cancer: Challenges and Opportunities
Kuipers, M. E., Wink, K. C. J., Hiemstra, P. S., & Slats, A. M. (2023) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2023.10.044 · Cited by 62
Mapping genetic modifiers of radiation-induced cardiotoxicity to rat chromosome 3
Schlaak, R. A., Frei, A. C., Schottstaedt, A. M., Tsaih, S., Fish, B. L., Harmann, L. M., Liu, Q., Gasperetti, T., Medhora, M. M., North, P. E., et al. (2019) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00482.2018 · Cited by 37
“Nrf2 has also been shown to promote against irradiation a number of nonmalignant cell types, including mouse embryonic fibroblasts (39, 52) and breast and lung epithelial cells (12).”
BackgroundReisman, S. A., Goldsberry, A., Lee, C. I., O’Grady, M. L., Proksch, J. W., Ward, K. W., & Meyer, C. J. (2015) · BMC Dermatology · doi:10.1186/s12895-015-0029-7 · Cited by 33
“A recent study evaluated the radioprotective effects of RTA 402, a potent Nrf2 activator and closely related analog to RTA 408, in normal epithelial cells and a panel of cancer cells exposed to ionizing radiation [15].”
Background
Metadata
- Authors
- El-Ashmawy, M., Delgado, O., Cardentey, A., Wright, W. E., & Shay, J. W.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- King Abdulaziz University (SA)
- Corresponding author
- Shay, Jerry W.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-12-23
- Volume
- 9
- Issue
- 12
- Pages
- e115600
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC4275221
- OpenAlex
- W1977648215
- Cited by
- 19
- References
- 39
- Citations by year
- 2025: 2 · 2023: 1 · 2022: 3 · 2021: 1 · 2020: 2 · 2019: 3 · 2017: 1 · 2016: 1 · 2015: 5
- FWCI
- 1.83
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- Howard Hughes Medical Institute
- National Aeronautics and Space Administration (NNX09AU95G)
- University of Texas Southwestern Medical Center (P50CA70907)
- National Institutes of Health
- National Cancer Institute ((P50-CA70907, P50CA070907, SPORE P50CA70907)
- National Center for Research Resources (C06 RR 30414, C06RR030414)
- Topics
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Effects of Radiation Exposure
- Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Keywords
- bardoxolone methyl, synthetic triterpenoids, radiation protection, Nrf2, antioxidant response element, gamma radiation, lung epithelial cells, breast epithelial cells, radiation-induced DNA damage, dose modification factor, radiotherapy toxicity, human bronchial epithelial cells, lymphocytes, reactive oxygen species
- MeSH terms
- Animals, Antioxidants, Breast, Breast Neoplasms, Cell Line, DNA Damage, Epithelial Cells, Female, Humans, Lung, Lung Neoplasms, Oleanolic Acid, Radiation-Protective Agents, Signal Transduction, Cell Line, Tumor, NF-E2-Related Factor 2, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.